Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Faron Pharmaceuticals (FARN) Share Price

Price 250.00p on 15-04-2025 at 05:00:03
Change 0.00p 0%
Buy 0.00p
Sell 0.00p
Buy / Sell FARN Shares
Last Trade: Unknown 297.00 at 245.00p
Day's Volume: 0
Last Close: 250.00p
Open: 0.00p
ISIN: FI4000153309
Day's Range 0.00p - 0.00p
52wk Range: 89.00p - 270.00p
Market Capitalisation: £279m
VWAP: 0.00p
Shares in Issue: 112m

Faron Pharmaceuticals (FARN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 297 245.00p OTC Trade
17:39:56 - 14-Apr-25
Unknown* 135 250.00p OTC Trade
16:35:07 - 14-Apr-25
Unknown* 77 250.00p OTC Trade
16:35:07 - 14-Apr-25
Unknown* 234 250.00p Uncrossing Trade
16:35:07 - 14-Apr-25
Sell* 1,000 247.50p Ordinary
16:29:20 - 14-Apr-25
Buy* 700 252.00p Ordinary
16:16:09 - 14-Apr-25
Sell* 1 247.00p Ordinary
15:56:25 - 14-Apr-25
Buy* 296 250.00p Ordinary
14:54:47 - 14-Apr-25
Buy* 1,103 248.65p Ordinary
14:35:20 - 14-Apr-25
Sell* 60 245.50p Ordinary
13:55:43 - 14-Apr-25
See more Faron Pharmaceuticals trades

Faron Pharmaceuticals (FARN) Share Price History

Time period:
to
Date Open High Low Close Volume
14th Apr 2025 (Mon) 235.00 250.00 240.00 250.00 42,337
11th Apr 2025 (Fri) 226.50 235.00 235.00 235.00 9,561
10th Apr 2025 (Thu) 225.00 230.00 222.50 226.50 29,012
9th Apr 2025 (Wed) 226.50 228.00 220.00 222.00 46,366
8th Apr 2025 (Tue) 217.50 231.50 215.00 223.00 49,357
7th Apr 2025 (Mon) 205.00 215.00 215.00 215.00 56,125
4th Apr 2025 (Fri) 210.00 215.00 207.50 215.00 37,520
3rd Apr 2025 (Thu) 213.00 213.00 199.00 210.00 69,411
2nd Apr 2025 (Wed) 209.00 215.00 215.00 215.00 8,616
1st Apr 2025 (Tue) 213.00 213.00 209.00 209.00 5,494
31st Mar 2025 (Mon) 206.00 213.00 206.00 213.00 10,587
28th Mar 2025 (Fri) 216.00 216.00 206.00 206.00 13,433
27th Mar 2025 (Thu) 192.50 210.00 210.00 210.00 40,468
26th Mar 2025 (Wed) 190.00 192.50 190.00 192.50 2,786
25th Mar 2025 (Tue) 190.00 190.00 190.00 190.00 1,682
24th Mar 2025 (Mon) 190.00 192.50 190.00 192.50 27,690
21st Mar 2025 (Fri) 190.00 192.50 190.00 190.00 17,647
20th Mar 2025 (Thu) 187.50 190.00 187.50 190.00 9,756
19th Mar 2025 (Wed) 185.00 190.00 185.00 187.50 10,780
18th Mar 2025 (Tue) 182.50 185.00 182.50 185.00 14,134
17th Mar 2025 (Mon) 180.00 190.00 180.00 182.50 11,585
See more Faron Pharmaceuticals price history

Faron Pharmaceuticals (FARN) Regulatory News

Date Source Headline
3rd Mar 2025 12:05 pm RNS FDA Grants Orphan Drug Designation
28th Feb 2025 12:00 pm RNS Notice of Annual General Meeting
27th Feb 2025 7:30 am RNS Positive EMA Opinion on Orphan Drug Designation
27th Feb 2025 7:15 am RNS Annual Report 2024 published
27th Feb 2025 7:00 am RNS Financial Statement 1 January to 31 December 2024
19th Feb 2025 10:00 am RNS Notice of Financial Statement and Annual Report
14th Feb 2025 12:00 pm RNS Holding(s) in Company
11th Feb 2025 7:30 am RNS Change of Broker
6th Feb 2025 3:00 pm RNS Holding(s) in Company
6th Feb 2025 7:00 am RNS Results of Oversubscribed Placing
See more Faron Pharmaceuticals regulatory news

Faron Pharmaceuticals (FARN) Share News

UK shareholder meetings calendar - next 7 days

14th Mar 2025 14:09

Read More

UK earnings, trading statements calendar - next 7 days

20th Feb 2025 14:16

Read More

Faron Pharmaceuticals raises EUR12 million from oversubscribed placing

6th Feb 2025 11:41

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has raised EUR12 million from an oversubscribed placing ahead of upcoming trial results. Read More

IN BRIEF: Faron Pharmaceuticals shares up as presents data on Bexmab

10th Dec 2024 14:31

Faron Pharmaceuticals PLC on Tuesday - Turku, Finland-based developer of cancer immunotherapies - Presents full analysis of positive phase 2 interim data from Bexmab trial at the annual meeting of the Society of Hematology in San Diego. Faron highlights an overall response rate of 80% in refractory or relapsed HMA failed MDS patient population. HMA stands for hypomethylating agents, while MDS stands for myelodysplastic syndromes. Chief Executive Officer Juho Jalkanen says: "With this compelling evidence, we are well positioned to advance to the full phase 2 efficacy readout and actively pursue further regulatory interactions to navigate and refine the pivotal pathway for BLA filing." Read More

Faron announces promising findings from blood cancer drug trial

27th Nov 2024 11:29

(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday reported positive data from an ongoing trial on patients receiving a new treatment for a rare blood cancer. Read More

See more Faron Pharmaceuticals news
FTSE 100 Latest
Value8,134.34
Change0.00

Login to your account

Forgot Password?

Not Registered